PSMA-1-DOTA Potentially for Effective Targeted Radioligand Therapy of Prostate Cancer
PSMA-1-DOTA shows reduced uptake in salivary glands while effectively targeting PSMA-expressing tumors, thus potentially avoiding the side effects of xerostomia, and possibly moving PSMA-targeted RLT to a more frontline therapy for prostate cancer rather than the current use as a last resort.
Authors
- Maxim Sergeev
- Zhenghong Lee (ORCID: https://orcid.org/0000-0002-2429-9911)
- David Reichert (ORCID: https://orcid.org/0000-0002-9593-6447)
- James P. Basilion
- Wolfgang Weber (ORCID: https://orcid.org/0000-0002-7854-4345)
- Patrick Wojtylak
- Lifang Zhang (ORCID: https://orcid.org/0000-0001-8950-2936)
- Xinning Wang (ORCID: https://orcid.org/0000-0001-7729-0534)
- Olga Sergeeva (ORCID: https://orcid.org/0000-0003-0819-1967)
- Marc S. Berridge
- Zoey A. Lockwood
- Riley Sangster
Institutions
- University Hospitals of Cleveland (US)
- Arkansas Department of Agriculture (US)
- Nuklearmedizinische Klinik des Klinikums rechts der Isar (DE)
- Case Western Reserve University (US)
Publication Details
- Journal
- Molecular Imaging and Biology
- Published
- 2025-09-02
- DOI
- https://doi.org/10.1007/s11307-025-02046-9
- Citations
- 1
- Primary Topic
- Prostate Cancer Treatment and Research
- Type
- article
- Field-Weighted Citation Impact
- 1.52
Funders
- National Science Foundation
- Case Western Reserve University
- National Institutes of Health
- National Cancer Institute
- DOD Peer Reviewed Cancer Research Program